Consultation.

Abstract

Private applicant proposal (agenda item 2.2) – PSA does not support this proposal which would result in cannabidiol preparations with cannabidiol as 98 per cent or greater of total cannabinoid content and 0.2 per cent or less of tetrahydrocannabinol content being exempt from scheduling. This is based on PSA’s significant concerns around safety implications for patients and carers, as well as the broader public.